Trials Sponsors Conditions Drugs Pricing

Conditions

Non Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

PFS2 at two years is the primary endpoint of the study

Secondary Outcomes (5)

OS
ORR
DoR
TRAEs
HRQoL

Interventions

Lazcluze 240 mg film-coated tabletsType not reported

Tafinlar 50 mg hard capsulesType not reported

Braftovi 50 mg hard capsulesType not reported

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Tafinlar 50 mg hard capsules
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry record
Formulated product
Braftovi 50 mg hard capsules
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry record
Formulated product
Tecentriq 1 200 mg concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry record
Formulated product
YERVOY 5 mg/ml concentrate for solution for infusion
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INFUSION
View registry record
Formulated product
LUMYKRAS 120 mg film-coated tablets

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

Tafinlar 50 mg hard capsules
Named ingredient: dabrafenib
View registry record
Braftovi 50 mg hard capsules
Named ingredient: encorafenib
View registry record
Tecentriq 1 200 mg concentrate for solution for infusion
Named ingredient: atezolizumab
View registry record
YERVOY 5 mg/ml concentrate for solution for infusion
Named ingredient: Ipilimumab
View registry record
LUMYKRAS 120 mg film-coated tablets
Named ingredient: sotorasib
View registry record
Mektovi 15 mg film-coated tablets
Named ingredient: binimetinib
View registry record
Paclitaxel Fresenius Kabi 6 mg/ml koncentrat till infusionsvätska, lösning

Eligibility Criteria

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients of either sex aged ≥ 18 years
Histologically confirmed stage IIIB-C (unresectable and not eligible for chemoradiation) or stage IV NSCLC (AJCC Version 9).
Treatment naïve for metastatic disease patients. Previous adjuvant treatment with both targeted therapies and checkpoint inhibitors anti PD-1/PDL-1 is allowed. (if completed at least 12 months prior to randomization, with all related adverse events have either returned to baseline or stabilized).

Sponsors & Collaborators

Universita' Degli Studi Di Torino
Otherlead

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Sites (54)

Humanitas Istituto Clinico Catanese S.p.A.

Misterbianco, 95045, Italy

Alessandro Russo+3909573390813 alessandro.russo@humanitascatania.it

Azienda Unita' Locale Socio Sanitaria N. 2 Marca Trevigiana

Treviso, 31100, Italy

Adolfo Favaretto+390422322070 adolfo.favaretto@aulss2.veneto.it

Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli

Naples, 80131, Italy

Central Study Contacts

Francesco Passiglia

+390119026978 francesco.passiglia@unito.it

Study Design

Study Type: interventional
Phase: phase 2 3

Study Record Dates

First Submitted

June 30, 2026

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2026-525268-16-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 06:49:12 UTC

Documents

Protocol DYNAMIC v 1 of 30OCT2025

You may not qualify if:

Participant with current participation in any interventional clinical trial.
Participant who received any systemic therapy for advanced disease prior of initiating the protocol therapy.
Participant who received major surgery ≤3 weeks prior to initiating protocol therapy and/or has been recovered from any surgical effects
Participant who received radiation therapy within 2 weeks prior to Day 1 of protocol therapy.
Participant with known hypersensitivity to any study drugs components or excipients
Participant with a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
Participant with diagnosis, detection, or treatment of another type of malignancy ≤2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated).
Participant with known, symptomatic brain or leptomeningeal metastases. Subjects with brain metastases are eligible if these have been treated and there is no MRI evidence of progression for at least 4weeks after treatment is complete and within 28 days prior to first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. *For EGFR, ALK and RET positive patients who are candidates for upfront TKI therapy enrolment may be allowed following a case by case discussion with medica monitor
Participant with a diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding 10 mg of prednisone or equivalent daily) or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy (only for study arms including PD-1/PD-L1 inhibitors).
Participant with a known history of human immunodeficiency virus (type 1 or 2 antibodies) (only for study arms including PD-1/PD-L1 inhibitors).
Participant with a known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).
Participant with an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) (only for study arms including PD-1/PD-L1 inhibitors). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Participant with a known history of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment (only for study arms including PD-1/PD-L1 inhibitors).
Participant has received a live vaccine within 14 days of initiating protocol therapy.
Participant who is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 180 days after the last dose of study treatment
+1 more criteria

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (54)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (54)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations